Abstract
Get full access to this article
View all access options for this article.
References
1.
Gabriel
A
. Astellas Gene Therapies to Close Biomanufacturing Facility, Affecting About 100 Employees . BioSpace . September 3, 2024 . Available from: https://www.biospace.com/job-trends/astellas-gene-therapies-to-close-biomanufacturing-facility-affecting-about-100-employees [Last accessed:
September 12 , 2024
].
2.BridgeBio Pharma . BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) . September 10, 2024 . Available from: https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-topline-results-phase-12-trial [Last accessed:
September 14 , 2024
].
3.Atsena Therapeutics . Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet . September 5, 2024 . Available from: https://atsenatx.com/press-release/atsena-therapeutics-announces-12-month-safety-and-efficacy-data-from-phase-i-ii-clinical-trial-of-atsn-101-in-lca1-published-in-the-lancet/ [Last accessed:
September 15 , 2024
].
4.
Yang
P
,
Pardon
LP
,
Ho
HC
, et al. Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: A phase 1/2, multicentre, open-label, unilateral dose escalation study . Lancet , 2024 ; 404 (10456 ):962 –970 . https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01447-8/fulltext (September 15, 2024 ).
5.Sonoma Biotherapeutics . Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing Collaboration . September 4, 2024 . Available from: https://sonomabio.com/2024/09/sonoma-biotherapeutics-receives-milestone-payment/ [Last accessed:
September 12 , 2024
].
6.YolTech Therapeutics . YolTech Announces Licensing Agreement with Salubris for the Development and Commercialization of YOLT-101 in Mainland China . August 27, 2024 . Available from: https://www.prnewswire.com/news-releases/yoltech-announces-licensing-agreement-with-salubris-for-the-development-and-commercialization-of-yolt-101-in-mainland-china-302231511.html [Last accessed:
September 15 , 2024
].
7.Vironexis Biotherapeutics . Vironexis Biotherapeutics Launches with FDA Clearance of IND Application for First-Ever Clinical Trial of an AAV-delivered Cancer Immunotherapy . September 12, 2024 . Available from: https://vironexis.com/vironexis-biotherapeutics-launches-with-fda-clearance-of-ind-application-for-first-ever-clinical-trial-of-an-aav-delivered-cancer-immunotherapy/ [Last accessed:
September 15 , 2024
].
8.Nanoscope Therapeutics . Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration . September 12, 2024 . Available from: https://nanostherapeutics.com/2024/09/12/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration/ [Last accessed:
September 15 , 2024
].